Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bristol-Myers Squibb Buys Medarex: Adds Eighth ‘Pearl' To String

Executive Summary

Bristol-Myers Squibb is buying the biotech company Medarex in a deal valued at $2.4 billion, or $16.00 per share in cash, the companies announced July 22. In doing so, Bristol gains full rights to the late-stage cancer drug ipilimumab and to innovative technologies for developing immunology and oncology humanized antibodies

You may also be interested in...



Bristol/Celgene A Record-Setting Merger, If It Happens

The $74bn mega-merger would be the third largest in biopharma history, but some analysts wonder if other suitors will try to acquire Bristol before the deal closes.

Bristol/Celgene A Record-Setting Merger, If It Happens

The mega-merger would be the third largest in biopharma history, but some analysts wonder if other suitors will try to acquire Bristol before the deal closes. Celgene’s partners, and their investors, are concerned about the ramifications.

Sanofi/Regeneron's IO Springboard Libtayo Cleared For Skin Cancer

In addition to skin cancer, the PD-1 inhibitor cemiplimab is being positioned for a range of other tumor types with Phase III studies ongoing in lung and cervical cancers.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS051296

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel